AlphaValue cuts Lanxess to 'reduce', lowers EBITDA estimates on softer demand

LANXESS AG

Thu 08:13

** AlphaValue cuts Speciality chemicals maker Lanxess LXSG.DE to "reduce" from "buy" citing more cautious stance for a weak balance sheet
** "We have cut our FY2026 and FY2027 EBITDA estimates by ~4% and ~3%, respectively, to account for a softer demand backdrop," the broker says
** This reflects benefits from German fiscal stimulus being deferred to 2027, alongside risks from rising interest rates and a partial return of Chinese competition, it adds
** AlphaValue now estimates Lanxess' EBITDA to come in at €501 million  ($577.15 million), in line with the group's target range of €450-550 million but below the €510 million figure recorded in 2025 
** Out of 22 analysts, four rate the stock "strong buy" or "buy,"​ 12 rate it "hold" and six "strong sell" or "sell" - LSEG data
** The stock is down 4.4%, underperforming the wider European chemicals index .SX4P which falls by 0.8%


($1 = 0.8681 euros)

 (Reporting by Anastasiia Kozlova)
 ((Anastasiia.Kozlova@thomsonreuters.com))